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Short summary: Curable sexually transmitted infections in pregnant women may cause poor 
maternal and newborn outcomes worldwide. Syndromic management is practiced in many 
settings yet fails to identify most infections. Etiologic screening has promise but further 
effectiveness and cost-effectiveness studies are needed. 
 
This is an open-access article distributed under the terms of the Creative Commons Attribution-
Non Commercial-No Derivatives License 4.0 (CCBY), where it is permissible to download and 
share the work provided it is properly cited. The work cannot be changed in any way or used 
commercially without permission from the journal. AC
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Abstract 
Background: Sexually transmitted infections (STI), such as chlamydial, gonorrheal, and 
trichomonal infection, are prevalent in pregnant women in many countries and are widely 
reported to be associated with increased risk of poor maternal and neonatal outcomes. Syndromic 
STI management is frequently used in pregnant women in low- and middle-income countries, yet 
its low specificity and sensitivity lead to both over- and undertreatment. Etiologic screening for 
chlamydial, gonorrheal, and/or trichomonal infection in all pregnant women combined with 
targeted treatment might be an effective intervention. However, the evidence base is insufficient 
to support development of global recommendations. We aimed to describe key considerations 
and knowledge gaps regarding chlamydial, gonorrheal, and trichomonal screening during 
pregnancy to inform future research needed for developing guidelines for low- and middle-
income countries. 
Methods: We conducted a narrative review based on PubMed and clinical trials registry searches 
through January 20, 2020, guidelines review, and expert opinion. We summarized our findings 
using the frameworks adopted by the World Health Organization for guideline development.  
Results: Adverse maternal-child health outcomes of potential interest are wide-ranging and 
variably defined. No completed randomized controlled trials on etiologic screening and targeted 
treatment were identified. Evidence from observational studies was limited and trials of 
presumptive STI treatment have shown mixed results. Subgroups that might benefit from 
specific recommendations were identified. Evidence on harms was limited. Cost-effectiveness 
was influenced by STI prevalence and availability of testing infrastructure and high-
accuracy/low-cost tests. Preliminary data suggested high  patient acceptability.  
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Discussion: Preliminary data on harms, acceptability, and feasibility and the availability of 
emerging test technologies suggest that etiologic STI screening deserves further evaluation as a 
potential tool to improve maternal and neonatal health outcomes worldwide. 
Key words: sexually transmitted diseases, pregnancy, screening, developing countries 
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1. Introduction 
The curable sexually transmitted infections (STI) Chlamydia trachomatis, Neisseria 
gonorrhoeae, and Trichomonas vaginalis are common in pregnant women in many countries. 
Regional estimates of STI prevalence among pregnant women vary(1): N. gonorrhoeae, 1.2% 
(Latin America) to 4.6% (Southern Africa), C. trachomatis, 0.8% (Asia) to 11.2% (Latin 
America), and T. vaginalis, 3.9% (Latin America) to 24.6% (Southern Africa). While it is 
difficult to fully elucidate their relative impact, multiple studies have found associations between 
these three STIs and increased risk of poor maternal and neonatal outcomes (e.g., miscarriage, 
stillbirth, preterm birth, low birthweight, and mother-to-child HIV transmission).(2-6)  
 
Few countries recommend routine screening for chlamydial, gonorrheal, or trichomonal infection 
in pregnant women.(7) The World Health Organization (WHO) recommends screening for HIV 
infection and syphilis(8) but has no specific guidelines for other STIs beyond syndromic 
management which limits treatment to symptomatic women.(9) The frequently asymptomatic 
nature of STIs in women is well established(10) and syndromic management fails to identify the 
majority of infected women. Syndromic management has modest sensitivity (40% to 75%) and 
specificity (54% and 76%) for detecting chlamydial and/or gonococcal infection.(10) A study of 
HIV-infected pregnant women in South Africa found that only 24% of women who tested 
positive for a chlamydial, gonococcal, or trichomonal infection had vaginal symptoms 
(sensitivity), whereas 47% of those with symptoms were negative for all three infections 
(specificity).(11) The poor specificity and sensitivity of syndromic management lead to both 
over- and undertreatment. Poor antimicrobial stewardship may increase the risk of antibiotic 
resistance.(12) 
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The prevalence of, and likely adverse outcomes associated with, curable STIs in pregnant 
women suggest that etiologic STI screening of all pregnant women followed by targeted 
treatment might be beneficial. However, the evidence base around that intervention is 
insufficient to support development of global recommendations. WHO uses a systematic process 
for developing guidelines(13) based, in part, on the Population, Intervention, Comparator, 
Outcomes (PICO) and Grading of Recommendations, Assessment, Development and 
Evaluations (GRADE) frameworks for formulating the question and assessing the benefits, 
harms, and other relevant factors. This narrative review aimed to describe key considerations and 
knowledge gaps regarding etiologic STI screening during pregnancy using the PICO and 
GRADE frameworks. We also aimed to identify key studies in progress that may contribute to 
addressing these knowledge gaps. Our goal was to inform future research contributing to the 
evidence needed for developing guidelines, particularly for low- and middle-income countries. 
 
2. Materials and Methods 
This narrative review drew on focused PubMed literature searches, review of WHO and other 
agency guidelines, and expert opinion. International public health and clinical experts from 
academia, government, industry and community-based organizations met on July 14, 2019 in 
Vancouver, British Columbia, Canada to frame the initial inquiry. Presentations and discussion 
during the meeting were the initial source of information for the review. PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed) and clinical trials registry (https://clinicaltrials.gov and 
http://www.isrctn.com) searches conducted through January 20, 2020 were developed iteratively 
based on initial searches using the terms ‘pregnancy’ and ‘screening,’ and ‘sexually transmitted 
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infections,’ ‘chlamydia,’ ‘gonorrhea,’ or ‘trichomonas.’ PubMed searches initially focused on 
review articles. Reference lists were examined to identify relevant studies. Randomized 
controlled trials, observational studies, modeling, and qualitative studies related to STI 
screening/treatment and presumptive STI treatment were examined. We limited our review to 
studies where the full-text was available in English. Since this was not a systematic review, 
literatures searches were not conducted systematically, and identified studies and articles were 
not assessed using standardized criteria. 
 
We presented findings using the PICO and GRADE Evidence to Decision frameworks for health 
system/public health decisions(14) and for tests in clinical practice and public health.(15). The 
population (pregnant women in low- and middle-income countries), intervention (etiologic 
screening for C. trachomatis, N. gonorrhoeae, and/or T. vaginalis of all pregnant women 
followed by treatment and case management of those with positive test results), and comparator 
(syndromic STI management) were pre-determined by the authors to delineate the scope of the 
project. We examined the following GRADE domains: priority/importance, test accuracy, 
desirable effects (benefits), undesirable effects (harms), resource requirements/cost-
effectiveness, equity, acceptability, and feasibility. We did not formally address the quality of 
available evidence or develop recommendations. 
 
3. Findings 
Formulating the key question using the PICO format and selecting outcomes are critical initial 
steps in the WHO guideline process.(13) (Figure 1) The population, intervention, and comparator 
were selected a priori by the authors. The adverse outcomes of potential interest were wide-
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ranging. In meta-analyses of associations between chlamydial infection and adverse pregnancy 
outcomes, women with chlamydial infection had increased risk of preterm labor/birth, perinatal 
mortality, stillbirth, intrauterine fetal demise, and newborn low birthweight/birth size compared 
to those without chlamydial infection.(4, 5) The strength of those associations was attenuated in 
adjusted analyses and higher quality studies. Chlamydial infection was found to increase mother-
to-child HIV transmission by almost 50% in one study.(3) A meta-analysis of trichomonal 
infection in pregnancy found that infected women had a 41% increased risk of preterm birth and 
51% increase in having small for gestational age newborns compared to those without 
trichomonal infection.(2) We did not identify any meta-analyses on maternal gonococcal 
infection, however maternal gonococcal infection has been associated with preterm birth, low 
birthweight, and neonatal eye infections.(6) 
 
Outcome definitions varied substantially among studies. Outcomes related to birth size have 
been examined using 1) mean birthweight,(16) 2) low birthweight categorization based in weight 
(<2500g)(17, 18) or chest/head circumference,(19) or 3) intrauterine growth restriction 
categorization based on weight or height (<10th percentile).(18) In some studies gestational age 
was measured using ultrasound, a highly accurate method,(20) whereas others used self-reported 
date of last menstrual period or fundal height which is less accurate. Other outcome measures 
had similarly variable definitions across studies. 
 
Subgroups: We identified several patient and population-level subgroups that might benefit 
from specific recommendations. Pregnant women living with HIV infection may have higher 
STI prevalence(21) and a higher risk of poor birth outcomes(22) than those without HIV 
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infection which may modify the effect of screening interventions. In malaria-endemic areas, 
sulfadoxine-pyrimethamine for intermittent preventive treatment in pregnant women may have 
some efficacy against CT and NG and associated adverse birth outcomes.(18) As such, local 
implementation of intermittent preventive treatment for malaria(23) could also influence the 
need for specific recommendations. Geographic heterogeneity in health systems and the 
distribution of STIs and HIV infection(1) might indicate other identifiers of sub-groups. 
 
Figure 2 summarizes the GRADE Evidence to Decision domains. 
Priority/importance: Improved maternal-child health is a primary target of the UN Sustainable 
Development Goals(24) and addressing STIs will contribute to meeting these targets. The high 
prevalence of STIs in pregnant women in low- and middle-income countries is established(1) 
and treatments are widely available and easy to administer.(25, 26) However, the magnitude of 
the impact of treating STIs in pregnant women on poor maternal-child outcomes has not yet been 
fully elucidated (see Benefits), a necessary step for establishing this area as a priority for 
intervention.  
 
Benefits and desirable effects: The benefits of etiologic screening and treating curable STIs in 
pregnancy in low- and middle-income countries, apart from syphilis,(9) have not been rigorously 
examined. We did not identify any completed clinical trials on etiologic gonococcal, chlamydial, 
or trichomonal screening in pregnant women in low- and middle-income countries. Some 
observational studies from high-income countries support chlamydial screening for improving 
pregnancy outcomes but generalizability to low- and middle-income countries is unclear.(21) 
Multiple authors of reviews and meta-analyses reported that insufficient information on 
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confounders, including timing of infection versus testing/treatment, diagnosis of other infections, 
and other causes of poor maternal-child health outcomes, complicated interpretation of the 
available evidence.(4, 21, 27) 
 
Trials of presumptive STI treatment in pregnant women to improve maternal/neonatal outcomes 
provide information that may help elucidate the potential impact of screening and treatment.(16, 
17, 19) A cluster randomized controlled trial among ~4000 pregnant women in Uganda(19) 
found that one-time treatment with azithromycin 1g, cefixime 400mg, and metronidazole 2g, 
which were effective against NG, CT, TV, chancroid, and bacterial vaginosis, as well as several 
non-STI pathogens, resulted in a 17% decrease in early neonatal deaths and 47% improvement in 
birth weight compared with syndromic STI management. No effects on stillbirth, maternal 
deaths, or preterm delivery were identified. Three randomized trials of intermittent treatment for 
malaria in pregnancy were relevant. In Malawi,(17) pregnant women received sulfadoxine-
pyrimethamine 1500mg/75mg for malaria prevention and azithromycin 1g, effective against NG, 
CT, and a variety of non-STI pathogens, during the second and third trimesters or placebo. The 
authors found a 34% decrease in preterm delivery and a 36% decrease in low birthweight among 
those that received azithromycin compared with placebo. No differences in perinatal or neonatal 
mortality were found. A second trial in Malawi(16) that compared presumptive azithromycin 1g 
+ sulfadoxine-pyrimethamine 1000mg/50mg during the second and third trimesters with placebo 
+ sulfadoxine-pyrimethamine found no significant impacts on preterm birth, gestational age at 
birth, mean birthweight, or perinatal death. In Papua New Guinea, presumptive azithromycin 1g 
+ sulfadoxine-pyrimethamine 1500mg/75mg compared with sulfadoxine-pyrimethamine and 
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chloroquine 450mg–600mg in ~2000 pregnant women resulted in a 26% lower prevalence of 
low birthweight and 38% lower risk of preterm delivery.(28) 
 
Insufficient knowledge of the effects of STIs at different gestational ages on birth outcomes 
limits our ability to optimize the timing of etiologic screening and treatment. Administration of 
presumptive STI treatment in the above trials varied from one-time treatment at any point during 
pregnancy(19) to monthly treatment during 14-26 weeks gestation until delivery.(17) Even if 
successfully treated, women can be re-infected during pregnancy if partners are not treated. 
Unfortunately, the effectiveness of partner management in these settings has not been fully 
examined. Additionally, the physiologic mechanisms by which chlamydial, gonococcal, and 
trichomonal infection impact birth outcomes are complex and unclear.(21, 29)  
 
The Table shows the status of ongoing studies on the effectiveness of etiologic screening and 
treatment in pregnancy. Randomized controlled trials are underway in China(30) and Papua New 
Guinea,(29) and in the planning stages in Botswana and South Africa. A prospective cohort 
study was recently completed in Brazil.(31) A comparative-effectiveness study is in the planning 
stages in Ethiopia. Studies in Cameroon,(32) Kenya, Tanzania, and Malawi,(33) Mali,(34) and 
Zambia(35) are examining the impact of presumptive STI treatment, usually coupled with 
preventive malaria therapy.  
 
Harm and undesirable effects: Evidence of harm from etiologic STI screening and treatment 
studies in low- and middle-income countries was limited. Publications of large clinical trials on 
presumptive STI treatment have not reported worse birth outcomes compared with control 
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interventions.(16, 17, 19, 28) In a trial of presumptive treatment in Papua New Guinea, numbers 
of adverse events were similar between in the control and intervention arms.(28) In one trial in 
the USA, treatment of asymptomatic trichomonal infection in pregnant women was associated 
with increased preterm birth(36) but the selected intervention (two 2g doses of metronidazole 48-
hours apart at 16-23 weeks and 24-29 weeks gestation) was non-standard.  
 
Harm attributable to antibiotic use during pregnancy is possible, however STI treatment 
guidelines were designed to minimize potential harm.(25, 26) While increasing antibiotic use can 
lead to increased antimicrobial resistance, treatment based on etiological test results rather than 
syndromic management should reduce overtreatment and decrease selective pressure for 
antimicrobial resistance. However, the effects on STI antimicrobial resistance have not been 
studied empirically. The presumptive STI treatment trial in Zambia(35) is investigating 
antimicrobial resistance in the vaginal microbiome. 
 
STIs are often stigmatized(12) and have been associated with intimate partner violence(37) and 
fear of intimate partner violence.(38, 39) However, many studies have reported very high rates of 
acceptance of partner notification(38-41), suggesting that concerns about intimate partner 
violence and stigma around STIs were not a significant barrier for most women. The trial 
underway in Papua New Guinea(29) is examining intimate partner violence as an adverse event. 
 
Test accuracy: Culture-based STI testing requires trained laboratory staff, specialized specimen 
transport and equipment, and has long turn-around times and low sensitivity.(42, 43) 
Consequently, STI diagnostics have moved toward molecular testing in many settings.(42) While 
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molecular tests also require specialized equipment, some can be conducted in low-resource 
clinical settings at or near the point-of-care rather than in a laboratory.(43, 44) Reported accuracy 
of those tests varied substantially but studies of some platforms (e.g., GeneXpert®, Cepheid®, 
Sunnyvale, CA, US) have shown accuracies of >95%.(42, 44) Studies in progress on etiologic 
STI screening are all using molecular methods for chlamydial and gonococcal screening.(Table) 
Tests for trichomonal infection are either molecular or immunochromatographic assays.  
 
Resource requirements: Cheap antibiotics for STI treatment are widely available but accurate 
diagnostic tests are relatively expensive. In 2019, the Foundation for Innovative New 
Diagnostics negotiated a GeneXpert® C. trachomatis/N. gonorrhoeae test cartridge price of 
US$16.20/test for low- and middle-income countries,(45) which excludes specimen collection 
supplies and the test platform (US$17,000 one-time cost). Such pricing is well above the 
US$1/test threshold some experts have suggested is needed to implement etiologic STI testing in 
low- and middle-income countries.(43) Substantially lower test accuracies have been reported for 
more affordable test options.(42, 44) 
 
Cost-effectiveness studies in Australia and the USA compared chlamydial screening in younger 
pregnant women with no screening.(46, 47) When considering costs associated with adverse 
outcomes averted, screening was cost saving at a chlamydial prevalence of 16.9% and 11%, 
respectively. Neither study considered overhead/capital costs or long-term population impacts of 
infections averted. Additionally, the evidence used in both studies to inform parameters related 
to short-term health outcomes was limited.  
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Different testing strategies could reduce costs and maximize impact. A modeling analysis of cost 
and effectiveness compared different antenatal chlamydial and gonococcal screening strategies in 
Botswana with syndromic management.(48) Having GeneXpert® equipment available at every 
antenatal care facility was the most expensive option but resulted in the most infections treated 
and cured. Syndromic management was the least expensive strategy, but it resulted in fewer 
infections cured and considerable overtreatment. A hub-and-spoke approach, where testing 
occurred at high-volume facilities and low-volume facilities collected specimens and sent them 
to high-volume facilities for testing, offered the optimal cost per infection averted. Further 
examination of the costs associated with etiologic screening and treatment in pregnancy are 
planned for the etiologic STI screening trials in Botswana, Papua New Guinea, and South Africa, 
as well as the comparative-effectiveness study in Ethiopia and presumptive STI treatment trials 
in Mali and Zambia.(Table)  
 
Equity: A 2015-2016 survey of ministries of health found only fourteen countries, of which 
eleven were high income, with national antenatal screening policies for gonorrhea or 
chlamydia.(7) Given that pregnant women in low- and middle-income countries suffer from a 
disproportionate burden of STIs and poor maternal/neonatal outcomes,(24) access to etiologic 
STI screening could help improve health equity around reproductive health and 
maternal/neonatal outcomes. Although the potential magnitude of the impact global etiologic STI 
screening on health equity is unclear. 
 
Acceptability: Etiologic STI screening and treatment has been shown to be highly acceptable to 
pregnant women in low- and middle-income countries. In a combined analysis of 1,817 pregnant 
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women from six different studies, 93.3% of women approached agreed to be tested.(49) Most 
participants preferred self-collected vaginal swabs over physician-collected vaginal swabs; same-
day test results and treatment might have increased participation. In a Papua New Guinea pilot 
study using self-collected vaginal swabs, nearly all women approached wanted to participate.(50) 
Findings from a South African study also suggest very high (>95%) levels of acceptability.(51) 
Studies in Botswana, Brazil, and Papua New Guinea are examining acceptability among women, 
partners, and health care providers.(Table)  
 
Including sex partners in etiologic screening and treatment is necessary to prevent re-infection. 
Partner notification and treatment has been acceptable to pregnant women in multiple settings in 
low- and middle-income countries.(38-41) In one study from Brazil, 97% of women reported 
feeling comfortable asking their partners to attend antenatal care and 54-56% of partners did 
attend.(40) A follow-up study to examine further partner involvement and etiologic screening 
was recently completed.(31)(Table)  
 
Feasibility: Feasibility must be considered at both the facility and health system levels. Some 
etiologic STI tests can be conducted at or near the point-of-care, allowing for decentralized 
diagnostic services and enabling same-day testing and treatment in low-resource settings.(52) 
The six-study combined analysis discussed above reported high levels of feasibility across study 
sites (overall 96.7%) defined as the percentage of diagnosed women who received treatment.(49) 
The pilot in Papua New Guinea found that etiologic STI testing and treatment could be 
successfully implemented with same-day treatment.(50) In South Africa, 92% of 172 pregnant 
women with positive STI test results received same-day treatment.(51) While all of those studies 
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used molecular test platforms which require electricity, the findings suggest that etiologic STI 
screening and treatment can be operationalized in a variety of settings. 
 
Despite successes in research studies, access to test technologies is a substantial barrier to 
implementing sustainable etiologic screening globally. WHO has recommended the GeneXpert® 
platform to diagnose tuberculosis in low- and middle-income countries since 2013.(53) As a 
result, many low- and middle-income countries have some laboratory infrastructure to support 
molecular testing using GeneXpert®(53) which could be applied to STI diagnosis. However, the 
costs associated with those tests remain high, making the need for cost-effectiveness studies 
critical for determining feasibility. 
 
Studies in Papua New Guinea(29) and South Africa will examine operational feasibility of 
etiologic screening in select clinics.(Table) In Ethiopia investigators are examining feasibility at 
the regional health system level.(54)  
 
4. Discussion  
This review examined the evidence-gaps around etiologic STI screening in pregnancy in low- 
and middle-income countries for each of the GRADE criteria in order to guide ongoing research 
that could support the development of international guidelines. We did not find direct evidence 
on the impact of etiologic screening and treatment of gonococcal, chlamydial, and/or 
trichomonal infections on pregnancy outcomes in low- and middle-income countries. We found 
that differences in outcome definitions may contribute to future challenges with evaluating the 
evidence for eventual guidelines. Preliminary data on harms, acceptability, and feasibility 
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suggest that etiologic STI screening and treatment hold promise and merit further investigation, 
although a key challenge facing potential widespread implementation of this intervention is the 
high cost of and infrastructure needed for accurate etiologic STI tests. Potential harms should 
continue to be investigated but should not be considered a substantial barrier to further research. 
Current studies are further examining many of these challenges and knowledge gaps.  
 
This review had several limitations. First, the focused search strategies and study selection 
processes of a narrative review might have missed some relevant studies. Second, we did not 
formally rate the quality of the existing evidence since our focus was on identifying current 
research gaps. Third, this review was limited to a subset of common curable STIs, gonorrheal, 
chlamydial, and trichomonal infection. Guidelines for the detection and treatment of other 
treatable STIs that impact maternal and neonatal outcomes, most notably Mycoplasma 
genitalium and bacterial vaginosis, are also lacking(12, 55) but were beyond the scope of this 
effort due to limited evidence and testing options, lack of complete understanding of 
pathophysiology, and/or limited treatment options,  
 
Robust intervention trials examining the efficacy and potential harms of etiologic STI screening 
in antenatal settings are a priority. Additional research needs include: 
 Development of consistent outcome measures, particularly for gestational age, 
birthweight, and pregnancy loss, that allow for comparisons across studies and in meta-
analyses of individual-level data;  
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 Systematic recording of malaria prevalence and use of intermittent preventive therapy in 
affected areas given that such therapy may be protective against adverse birth outcomes 
among women with some STIs; 
 Integration of partner notification and treatment into intervention trials to examine the 
role of re-infection and the effectiveness of strategies such as at-home testing, expedited 
partner therapy, and incentives for partner testing; 
 Investigation of the influence of timing of etiologic STI screening and treatment during 
pregnancy as the ideal timing of STI screening during pregnancy is currently unknown 
and there is ongoing risk of re-infection; 
 Collection of data on intimate partner violence at study enrollment and incidents of 
violence during studies since intimate partner violence is both a potential confounder and 
adverse effect; 
 Collection of detailed cost data for performing cost-effectiveness analyses that consider 
STI prevalence, risk-based profile approaches to etiologic screening in low-resource 
settings, and availability of testing infrastructure to potentially guide the development of 
prevalence- or risk-based recommendations in resource-limited settings where the unit 
cost per test may otherwise be prohibitive;  
 Collection and dissemination of population-based STI prevalence data to inform national 
estimates of STI burden in pregnancy; 
 Collection of robust data on other factors associated with adverse pregnancy outcomes 
including other infections such as HIV, syphilis, M. genitalium, and bacterial vaginosis, 
maternal nutrition, maternal history of adverse birth outcomes, and anemia; 
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 Implementation research to examine operational and health system optimization for 
intervention delivery. 
 
Global health inequities and the association between STIs and poor pregnancy and newborn 
outcomes support the need to continue to develop and evaluate more effective interventions to 
improve maternal and neonatal health worldwide. While the magnitude of the effect of STIs on 
poor maternal-child health outcomes in low- and middle-income countries is still unknown, there 
is potential for substantial population-level impacts given the high prevalence of STIs in 
pregnant women in low- and middle-income countries and the relative ease of treatment. The 
current syndromic approach to STI management in pregnant women in low- and middle- income 
countries leads to both under- and over-diagnosis and treatment. Emerging technologies have 
created new opportunities for implementing more effective STI screening and treatment 
approaches which are now being evaluated in large randomized controlled trials. Research 
focused on addressing key knowledge gaps identified here will be central to generating a robust 
evidence base to inform the development of effective and sustainable interventions aimed at 
reducing the burden and consequences of curable STIs in pregnancy in low- and middle-income 
countries. 
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Table. Key characteristics of known studies in progress on non-syndromic management of chlamydia, gonorrhea, and/or trichomonas 
in pregnant women in low- and middle-income countries 
PI (Country) 
[reference] 
Study name 
Status 
Study design 
and target 
sample size 
Study 
population and 
inclusion 
criteria 
Study groups and 
interventions 
Outcomes 
Etiologic screening interventions 
Lee and 
Berhane 
(Ethiopia)  
ENAT 
 
Status: not yet 
recruiting 
Pragmatic 
comparative 
effectiveness 
study  
 
2x2 factorial 
design 
 
Target sample 
Pregnant 
women with 
first ANC visit 
at study health 
centers at ≤24 
weeks gestation 
based on last 
menstrual 
period and/or 
Health center randomization 
Group 1: Strengthening 
Ethiopian MOH/WHO- 
recommended nutrition 
interventions, including iron, 
folate, iodized salt, and local 
corn soya blend supplement to 
women with MUAC <23 cm 
 
Primary 
Birth weight; birth length 
 
Secondary 
Gestational age at delivery; preterm birth; 
small-for-gestational age; low birthweight; 
length-for age (at birth and 6 months); 
weight for age (at birth and 6 months); 
gestational weight gain; maternal anemia; AC
CE
PT
ED
30 
 
size: 3600 fundal height Group 2 (control): Nutrition 
standard of care 
 
Individual randomization 
All groups: Routine screening 
for HIV, syphilis, malaria 
 
Group 1: Urine culture and 
AST, molecular CT/NG testing 
(GeneXpert®1), symptomatic 
women screened for BV 
(BVBlue®1) and TV 
(OSOM®1) at enrollment using 
self-collected vaginal swabs; 
treat per test results; 
deworming in second and third 
stillbirth; cost-effectiveness 
AC
CE
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ED
31 
 
trimesters. 
 
Group 2: Standard of care 
screening urine dipstick; 
syndromic STI management 
 
 
Klausner, 
Morroni, Wynn 
(Botswana)  
 
Status: 
preparation 
Cluster 
randomized 
controlled 
crossover trial 
in 2 antenatal 
clinics 
 
500 women 
Pregnant 
women ≥18 
years old 
attending first 
ANC visit who 
are 
asymptomatic 
for CT/NG  
Group 1: Molecular CT/NG 
(GeneXpert®) screening using 
self-collected vaginal swabs at 
first ANC visit and again after 
27 weeks gestation; treat per 
test results; partner treatment 
provided when possible.  
 
Group 2 (control): Syndromic 
Primary 
Mother-to-child CT/NG transmission; 
newborn eye infection; newborn pneumonia  
 
Secondary 
Preterm birth; low birth weight; premature 
rupture of membranes; maternal STI 
diagnosed and treated; incremental cost-
effectiveness ratios, acceptability among A
CE
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ED
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STI management women and healthcare workers 
 
Medina-Marino 
and Klausner 
(South Africa) 
 
Status: not yet 
recruiting 
3-arm (1:1:1) 
individually 
randomized-
controlled 
hybrid-
effectiveness 
trial with 
economic 
evaluation  
 
2500 women 
(834 per arm) 
Pregnant 
women age≥18 
years attending 
first ANC visit 
at public 
antenatal clinic 
at <20 weeks 
gestation by 
ultrasound 
All groups: Routine screening 
for HIV and syphilis  
 
Group 1: Molecular screening 
for CT, NG and TV 
(GeneXpert®) at first ANC 
visit using nurse-collection 
vaginal swabs; treat per test 
results; tests-of-cure at 3 
weeks post-treatment 
 
Group 2: Molecular screening 
and treatment for CT, NG and 
TV (GeneXpert®) at first ANC 
Primary 
Change in maternal STI status between first 
ANC visit and birth; composite outcome: 
low birthweight, premature rupture of 
membranes, preterm birth, 
stillbirth/spontaneous abortion  
 
Secondary 
Implementation process evaluation; STI risk 
factors; mother-to-child STI transmission; 
neonatal STI colonization; cost-
effectiveness sub-study 
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visit using nurse-collection 
vaginal swabs; repeat 
screening at 30–34 weeks 
gestation; treat per test results 
 
Group 3 (control): Syndromic 
STI management 
 
Tang 
(China) (30)2 
 
Status: 
recruiting 
Individually 
randomized 
controlled trial 
in hospital-
based antenatal 
clinic 
 
200 women 
Pregnant 
women 18-45 
years old at first 
ANC visit to 
hospital-based 
clinic 
Group 1: Molecular CT/NG 
screening (Cobas®) of urine or 
vaginal swab on enrollment 
and during 37-40 weeks 
gestation; azithromycin 1g as 
per test results; test of cure at 1 
month, and 3 months after 
treatment as needed; patients 
Primary: 
Composite outcome: stillbirth, spontaneous 
abortion, preterm labor, premature rupture 
of membranes, small for gestational age, 
low birth weight, infant death, birth defects, 
neonatal conjunctivitis 
 
Secondary: AC
CE
PT
ED
34 
 
offered expedited partner 
therapy 
 
Group 2 (control): Syndromic 
STI management; molecular 
CT/NG testing (Cobas®) 
during 37-40 weeks gestation 
 
Stillbirth; spontaneous abortion; preterm 
labor; premature rupture of membranes; 
infant death; birth defects; neonatal 
conjunctivitis and pneumonia; screening 
rate; treatment rate; cure rate; partner 
treatment; costs of testing and treatment 
Vallely and 
Pomat (Papua 
New Guinea) 
(29) 
WANTAIM 
 
Status: 
recruiting 
Cluster 
randomized 
controlled 
crossover trial 
in 10 health 
centers 
 
4600 women 
Women ≥16 
years old 
attending ANC 
at ≤26 weeks 
gestation by 
ultrasound 
All groups: HIV and syphilis 
screening 
 
Group 1: Molecular CT/NG 
and TV (GeneXpert®) and BV 
(BVBlue®) screening using 
self-collected vaginal swabs at 
4 weeks post-enrollment and 
Primary 
Composite outcome: preterm birth, low 
birthweight 
 
Secondary 
Premature rupture of membranes; maternal 
STI diagnosed and treated; incremental 
cost-effectiveness ratios; health system AC
CE
PT
ED
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34-36 weeks gestation; treat 
per test results; partner 
treatment provided when 
possible  
 
Group 2 (control): Syndromic 
STI management 
 
implementation requirements; acceptability 
among women and healthcare workers; 
newborn eye infection; newborn 
pneumonia; mother-to-child STI 
transmission; test accuracy for neonatal 
infection 
 
Presumptive treatment interventions 
Chico and 
Chandramohan 
(Zambia) (35s) 
ASPIRE 
 
Status: 
recruiting 
3-arm 
individually 
randomized 
controlled trial 
 
5,436 pregnant 
women (1,812 
HIV-negative 
pregnant 
women who 
have not yet 
started IPTp3 
16-28 weeks 
gestation by 
All groups: HIV and syphilis 
screening; syndromic STI 
management 
 
Group 1: Monthly IPTp-SP3; 
metronidazole 2g at first and 
second ANC visit 
Primary 
Composite outcome: spontaneous abortion, 
stillbirth, small for gestational age, low 
birthweight, preterm delivery, neonatal 
mortality 
 
Secondary AC
CE
PT
ED
36 
 
per group)  
 
ultrasound   
Group 2: Monthly IPTp-DP3; 
metronidazole 2g at first and 
second ANC visit 
 
Group 3 (control): monthly 
IPTp-SP; placebo at first and 
second ANC 
 
Individual components of composite 
outcome; neonatal length and stunting; 
clinical malaria; malaria parasitemia; 
placental malaria; maternal anemia; 
congenital anemia; congenital malaria; TV 
and BV treatment efficacy; GI side effects; 
maternal NG, CT, TV, and syphilis 
infection; maternal vaginal microbiota; 
inflammation markers; AST of cultured 
isolates from vaginal swabs in symptomatic 
women; intervention costs; maternal and 
healthcare preferences for treatments 
 
Dionne-Odom 
(Cameroon) 
(32s) 
Individually 
randomized 
controlled trial  
HIV-positive 
pregnant 
women 
Group 1: IPTp with daily 
trimethoprim-
sulfamethoxazole DS; monthly 
Primary 
Plasmodium falciparum peripheral 
parasitemia; composite outcome: CT, NG, AC
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PREMISE 
 
Status: 
recruiting 
 
310 pregnant 
women 
16-55 
<28 weeks 
gestation by 
dates/fundal 
height or 
ultrasound 
azithromycin 1g x 3d 
 
Group 2 (control): IPTp with 
daily trimethoprim-
sulfamethoxazole DS; monthly 
placebo x 3d 
 
and syphilis infection 
 
Secondary 
Birthweight; symptomatic malaria; parasite 
density; placental malaria; maternal anemia; 
Group B streptococcus colonization; 
Mycoplasma genitalium infection; 
composite adverse birth outcome: low birth 
weight, miscarriage, preterm delivery, 
small-for-gestational age, congenital 
anomaly, early neonatal mortality; maternal 
adherence  
 
Kotloff (Mali) 
(34s) 
 
Three-cohort 
individually 
randomized 
Pregnant 
women 
attending ANC 
Groups 1 and 7 (cohorts 1 and 
3, respectively): Maternal oral 
azithromycin 2g at 2nd and 3rd 
Primary 
Infant mortality from 6 weeks through 6-12 
months of age; composite outcome: AC
CE
PT
ED
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Status: not yet 
recruiting 
controlled trial 
 
Cohort 1 (rural) 
2x2 factorial 
design with 
mothers and 
infants 
randomized 
separately 
(Groups 1-4) 
 
Cohort 2 (rural 
infant-only): 
infants 
randomized 
(Groups 5 and 
visit during 13-
37 weeks 
gestation by 
fundal height 
and/or maternal 
report of 
quickening 
 
Unborn infants 
enrolled with 
mothers. Cohort 
2 infants 
enrolled during 
routine 
vaccination 
visits 
trimester ANC visits and 
during delivery; infant oral 
azithromycin at 6 and 14 week 
visits 
 
Group 2 (cohort 1): Maternal 
oral azithromycin 2g at 2nd and 
3rd trimester ANC visits and 
during delivery; infant placebo 
at 6 and 14 week visits 
 
Group 3 (cohort 1): Maternal 
placebo at 2nd and 3rd trimester 
ANC visits and during 
delivery; infant oral 
azithromycin at 6 and 14 week 
stillbirth, infant mortality through 6-12 
months of age;  
 
Secondary 
Gestational age at birth; birth weight; 
incremental cost-effectiveness ratio 
AC
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ED
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6) 
 
Cohort 3 
(urban): 
Mothers/infants 
randomized in 
tandem (Groups 
7 and 8) 
 
99,700 
participants 
 
visits 
 
Groups 4 and 8 (cohorts 1 and 
3, respectively): Maternal 
placebo at 2nd and 3rd trimester 
ANC visits and during 
delivery; infant placebo at 6 
and 14 week visits 
 
Groups 5 and 6 (cohort 2): No 
maternal intervention; infant 
oral azithromycin at 6 and 14 
week visits versus placebo 
 
ter Kuile and 
Madanitsa 
3-arm (1:1:1) 
individually 
HIV-negative 
pregnant 
Group 1: Monthly IPTp-DP; 
placebo at first ANC visit  
Primary 
Composite outcome: spontaneous abortion, AC
CE
PT
ED
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(Kenya, 
Tanzania, 
Malawi) (33s) 
 
Status: done 
recruiting 
randomized 
controlled trial 
 
4,680 pregnant 
women (1,560 
per group)  
 
women 16-28 
weeks gestation 
assessed by 
ultrasound who 
have not yet 
started IPTp 
 
Group 2: Monthly IPTp-DP; 
azithromycin 2g at first ANC 
visit 
 
Group 3 (control): Monthly 
IPTp-SP at ANC 
 
stillbirth, small for gestational age, low 
birthweight, preterm delivery, neonatal 
mortality 
 
Secondary 
Individual components of composite 
measure; neonatal length and stunting; 
clinical malaria; malaria parasitemia; 
placental malaria; maternal anemia; 
congenital anemia; congenital malaria; TV 
and BV treatment efficacy; GI side effects; 
maternal NG, CT, TV, and syphilis 
infection; maternal vaginal microbiota; 
inflammation markers; intervention costs 
 
Other interventions AC
CE
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Yeganeh, Brazil 
(31s) 
 
Status: 
completed, 
analysis 
ongoing 
 
Prospective 
cohort  
 
400 women and 
their partners 
Pregnant 
women >18 
years old with 
sexual partner 
for longer than 
3 months seen 
at community 
antenatal care 
clinics4 
 
Cohort: Women and partners 
screened for HIV, syphilis, 
hepatitis B and C (by lateral 
flow assay) and molecular 
CT/NG and TV (GeneXpert®) 
screening using self-collected 
vaginal swabs; STIs treated per 
test results 
Primary: 
STI diagnosis; partner attendance at ANC 
visits for STI testing; gestational age; 
birthweight; congenital anomalies 
 
Secondary: 
Demographics and behavioral factors; 
acceptance of testing; partner presence at 
ANC visits; partner STI diagnosis; partner 
acceptance of treatment and referral 
 
Abbreviations: AST: antimicrobial susceptibility testing; ANC: antenatal care visit; BV: Bacterial vaginosis; CT, Chlamydia 
trachomatis; DALY: disability-adjusted life year; NG: Neisseria gonorrhea; STI: sexually transmitted infection; TV: Trichomonas 
vaginalis 
1 GeneXpert®, Cepheid®, Sunnyvale, CA, US; BVBlue®, Gryphus Diagnostics, Knoxville, Tennessee, US; OSOM®, Sekisui 
Diagnostics, Burlington, Massachusetts, US; Cobas® Roche® Diagnostics, Rotkreuz, Switzerland AC
CE
PT
ED
42 
 
2 Referenced protocol is for completed pilot study; authors are using same protocol for current randomized controlled trial. 
3 IPTp: intermittent preventive therapy for malaria in pregnancy; IPTp-SP: intermittent preventive therapy in pregnancy using 
sulfadoxine-pyrimethamine; IPTp-DP: intermittent preventive therapy in pregnancy using dihydroartemisinin–piperaquine. 
Sulfadoxine-pyrimethamine is recommended by WHO to protect against adverse birth outcomes attributable to malaria in endemic 
countries.(23) Sulfadoxine is a sulfanomide and may confer some protective effect against adverse birth outcomes among pregnant 
women with NG, CT, and TV and bacterial vaginosis.(18)  
4 Women with a history of intimate partner violence were excluded. 
Source: Studies were identified through searches of clinicaltrials.gov and ISRCTN.org, and co-author personal knowledge.  
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https://clinicaltrials.gov/ct2/show/NCT04189744. Accessed 12/31/2019 2019. 
36s. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm 
delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N 
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